Patient-derived xenograft (PDX) models are emerging as a transformative tool in colorectal cancer (CRC) research, offering unparalleled insights into tumor biology, drug resistance, and personalized treatment approaches. These models, created by transplanting fresh human tumor tissue into immunodeficient mice, faithfully replicate the genetic, histological, and molecular features of the original tumors. As such, they serve as invaluable resources in the study of tumor heterogeneity and in the development of precision oncology.

Emerging research highlights the transformative potential of m6A RNA modification in the diagnosis and treatment of cardiovascular diseases (CVDs). As the most abundant internal modification of eukaryotic RNA, m6A is pivotal in regulating gene expression, RNA metabolism, and cellular processes. Understanding its role in CVDs could revolutionize therapeutic strategies, offering new pathways to manage conditions like coronary artery disease (CAD), heart failure (HF), pulmonary hypertension (PH), and arrhythmias (AH).

An increase in nitrogen dioxide (NO₂) levels in the air is associated with a 7% rise in the risk of cardiac arrest over four days. Particulate matter (PM₂.₅ and PM₁₀) elevates the risk on the same day as the peak.

Researchers have developed a biomimetic mRNA delivery system that enhances the efficacy of PTEN mRNA in colorectal cancer immunotherapy. By using metal-ion coordination and cell-membrane coating, the system improves mRNA loading, cytosolic delivery, and stability, outperforming traditional lipid nanoparticles. The study also identifies a patient subgroup likely to benefit from PTEN-based treatment, provides an effective mRNA delivery system and conceptual proof for precise cancer immunotherapy.